Effects of antiepileptic drugs on lipids, homocysteine, and C‐reactive protein
The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Objective: The widely prescribed anticonvulsants phenytoin and carbamazepine are potent inducers of cytochrome P450 enzymes, which are involved in cholesterol synthesis. We sought to determine whether these drugs have an effect on cholesterol and other serological markers of vascular risk. Methods: We recruited 34 epilepsy patients taking carbamazepine or phenytoin in monotherapy whose physicians had elected to change treatment to one of the noninducing anticonvulsants lamotrigine or levetiracetam. Fasting blood samples were obtained both before and 6 weeks after the switch to measure serum lipid fractions, lipoprotein(a), C‐reactive protein, and homocysteine. A comparator group of 16 healthy subjects underwent the same serial studies. Results: In the epilepsy patients, switch from either phenytoin or carbamazepine produced significant declines in total cholesterol (−24.8mg/dl), atherogenic (non–high‐density lipoprotein) cholesterol (−19.9mg/dl), triglycerides (−47.1mg/dl) (all p < 0.0001), and C‐reactive protein (−31.4%; p = 0.027). Patients who stopped taking carbamazepine also had a 31.2% decline in lipoprotein(a) level ( p = 0.0004), whereas those taken off phenytoin had a decrease in homocysteine level (−1.7μmol/L; p = 0.005). All of these changes were significant when compared with those seen in healthy subjects ( p < 0.05). Results were similar whether patients were switched to lamotrigine or levetiracetam. Interpretation: Switching epilepsy patients from the enzyme‐inducers carbamazepine or phenytoin to the noninducing drugs levetiracetam or lamotrigine produces rapid and clinically significant amelioration in several serological markers of vascular risk. These findings suggest that phenytoin and carbamazepine may substantially increase the risk for cardiovascular and cerebrovascular disease. Ann Neurol 2009;65:448–456
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ridker, P. M., Hennekens, C. H., Buring, J. E., & Rifai, N. (2000) · New England Journal of Medicine · doi:10.1056/nejm200003233421202 · Cited by 5,850
Homocysteine and Risk of Ischemic Heart Disease and Stroke: A Meta-analysis
Homocysteine Studies Collaboration (2002) · JAMA · doi:10.1001/jama.288.16.2015 · Cited by 2,059
Homocysteine Lowering with Folic Acid and B Vitamins in Vascular Disease
(2006) · New England Journal of Medicine · doi:10.1056/nejmoa060900 · Cited by 1,729
Comparison of levetiracetam and controlled-release carbamazepine in newly diagnosed epilepsy
Brodie, M. J., Perucca, E., Ryvlin, P., Ben-Menachem, E., & Meencke, H.-J. (2007) · Neurology · doi:10.1212/01.wnl.0000252941.50833.4a · Cited by 467
Lange, L. A., Carlson, C. S., Hindorff, L. A., Lange, E. M., Walston, J., Durda, J. P., Cushman, M., Bis, J. C., Zeng, D., Lin, D., et al. (2006) · JAMA · doi:10.1001/jama.296.22.2703 · Cited by 266
Homocysteine-lowering therapy: a role in stroke prevention?
Spence, J. D. (2007) · The Lancet Neurology · doi:10.1016/s1474-4422(07)70219-3 · Cited by 220
Cited by
Adverse effects of antiepileptic drugs
Perucca, P., & Gilliam, F. G. (2012) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70153-9 · Cited by 694
Management of psychiatric and neurological comorbidities in epilepsy
Kanner, A. M. (2016) · Nature Reviews Neurology · doi:10.1038/nrneurol.2015.243 · Cited by 451
Enzyme induction with antiepileptic drugs: Cause for concern?
Brodie, M. J., Mintzer, S., Pack, A. M., Gidal, B. E., Vecht, C. J., & Schmidt, D. (2013) · Epilepsia · doi:10.1111/j.1528-1167.2012.03671.x · Cited by 383
Self-citationThe effect of antiepileptic drugs on thyroid hormonal function: causes and implications
Hamed, S. A. (2015) · Expert Review of Clinical Pharmacology · doi:10.1586/17512433.2015.1091302 · Cited by 56
Metadata
- Authors
- Mintzer, S., Skidmore, C. T., Abidin, C. J., Morales, M. C., Chervoneva, I., Capuzzi, D. M., & Sperling, M. R.
- Venue
- Annals of Neurology
- Publisher
- Wiley
- Published
- 2009-04
- Volume
- 65
- Issue
- 4
- Pages
- 448-456
- ISSN
- 0364-5134 (ISSN-L)
- 1531-8249
- OpenAlex
- W2150884892
- Cited by
- 221
- References
- 6
- FWCI
- 9.60
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.